Publication & Citation Trends
Publications
0 total
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks OA
Cited by 17
Semantic Scholar
75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study OA
Cited by 0
Semantic Scholar
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV OA
Cited by 43
Semantic Scholar
Pharmacology, Formulations, and Adverse Effects
Cited by 5
Semantic Scholar
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance OA
Cited by 12
Semantic Scholar
Cysteine/Glutathione Deficiency: A Significant and Treatable Corollary of Disease
Cited by 12
Semantic Scholar
A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans OA
Cited by 3
Semantic Scholar
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico OA
Cited by 0
Semantic Scholar
Research Topics
HIV/AIDS drug development and treatment
(86)
HIV Research and Treatment
(78)
HIV/AIDS Research and Interventions
(74)
HIV-related health complications and treatments
(21)
Pneumocystis jirovecii pneumonia detection and treatment
(21)
Affiliations
National Institutes of Health
Harvard University
Inserm
Palo Alto University
University of California, San Francisco